Nothing Special   »   [go: up one dir, main page]

ATE300950T1 - Chimäre cdna-klone des virus der infektiösen bursal-krankheit, expressionsprodukte und darauf basierende impfstoffe - Google Patents

Chimäre cdna-klone des virus der infektiösen bursal-krankheit, expressionsprodukte und darauf basierende impfstoffe

Info

Publication number
ATE300950T1
ATE300950T1 AT95914198T AT95914198T ATE300950T1 AT E300950 T1 ATE300950 T1 AT E300950T1 AT 95914198 T AT95914198 T AT 95914198T AT 95914198 T AT95914198 T AT 95914198T AT E300950 T1 ATE300950 T1 AT E300950T1
Authority
AT
Austria
Prior art keywords
disease virus
bursal disease
infectious bursal
ibdv
strains
Prior art date
Application number
AT95914198T
Other languages
English (en)
Inventor
Vikram Vakharia
David B Snyder
Stephanie A Mengel-Whersat
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE300950T1 publication Critical patent/ATE300950T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT95914198T 1994-03-29 1995-03-29 Chimäre cdna-klone des virus der infektiösen bursal-krankheit, expressionsprodukte und darauf basierende impfstoffe ATE300950T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/219,262 US5788970A (en) 1994-03-29 1994-03-29 Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon
PCT/US1995/003772 WO1995026196A1 (en) 1994-03-29 1995-03-29 CHIMERIC INFECTIOUS BURSAL DISEASE VIRUS cDNA CLONES, EXPRESSION PRODUCTS AND VACCINES BASED THEREON

Publications (1)

Publication Number Publication Date
ATE300950T1 true ATE300950T1 (de) 2005-08-15

Family

ID=22818561

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914198T ATE300950T1 (de) 1994-03-29 1995-03-29 Chimäre cdna-klone des virus der infektiösen bursal-krankheit, expressionsprodukte und darauf basierende impfstoffe

Country Status (10)

Country Link
US (3) US5788970A (de)
EP (1) EP0755259B1 (de)
JP (2) JPH09510873A (de)
AT (1) ATE300950T1 (de)
AU (1) AU696656B2 (de)
CA (1) CA2186856A1 (de)
DE (1) DE69534354T2 (de)
DK (1) DK0755259T3 (de)
ES (1) ES2249769T3 (de)
WO (1) WO1995026196A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871744A (en) * 1996-09-05 1999-02-16 University Of Maryland-Biotechnology Inst. Method for generating birnavirus from synthetic RNA transcripts
EP0887412B1 (de) * 1997-05-26 2003-10-15 Akzo Nobel N.V. Rekombinanter Birnavirusimpfstoff
CA2238659C (en) 1997-05-26 2010-12-14 Akzo Nobel N.V. Recombinant birnavirus vaccine
US6231868B1 (en) * 1997-09-30 2001-05-15 University Of Maryland-Biotechnology Institute Method for generating nonpathogenic infections birnavirus from synthetic RNA transcripts
WO1999050419A2 (en) * 1998-03-31 1999-10-07 University Of Maryland Biotechnology Institute A method for generating nonpathogenic, infectious pancreatic necrosis virus (ipnv) from synthetic rna transcripts
WO2000012677A2 (en) * 1998-09-01 2000-03-09 The University Of Hong Kong Generation of recombinant infectious bursal disease viruses by reverse genetics technology and the use of the recombinant viruses as attenuated vaccines
US6492148B1 (en) * 1999-03-05 2002-12-10 Akzo Nobel Nv Genetically engineered cell culture adapted infectious bursal disease virus (IBDV) mutants
US6468984B1 (en) 1999-06-08 2002-10-22 Innovo Biotechnologies Ltd. DNA vaccine for protecting an avian against infectious bursal disease virus
EP1069187A1 (de) * 1999-07-14 2001-01-17 Stichting Dienst Landbouwkundig Onderzoek Mosaik-Virus der infectiösen Bursal-Krankheit enthaltender Impfstoff
WO2001092486A1 (en) * 2000-05-31 2001-12-06 Akzo Nobel N.V. Serotype chimeric ibdv strains
EP1296710A4 (de) * 2000-06-19 2004-05-12 Rahan Meristem Rekombinanter impfstoff gegen das für die bursal-krankheit verantwortliche virus(03.01.02)
EP1170302B1 (de) * 2000-07-07 2006-06-21 Intervet International BV Impfstoffe basierend auf Mutanten des Virus der infektiösen Bursal-Krankheit
US6485940B2 (en) 2000-07-07 2002-11-26 Akzo Nobel N.V. Broad spectrum infectious bursal disease virus vaccine
JPWO2002038753A1 (ja) * 2000-11-09 2004-03-18 渡辺　純一 病原体に感染した動物の病態または生存に影響を与える遺伝子のスクリーニング方法
US6936256B2 (en) * 2001-08-10 2005-08-30 University Of Maryland Biotechnology Institute Sub-unit vaccine for infectious pancreatic necrosis virus
US7431930B2 (en) 2002-03-01 2008-10-07 Intervet International B.V. Infectious bursal disease virus (IBDV) mutant expressing virus neutralising epitopes specific for classic-and variant IBDV strains
WO2003074552A1 (en) * 2002-03-01 2003-09-12 Akzo Nobel N.V. An infectious bursal disease virus variant
RU2340672C2 (ru) * 2003-03-24 2008-12-10 Интервет Интернэшнл Б.В. Мутант вируса инфекционной бурсальной болезни (ibdv), экспрессирующий вирус-нейтрализующие эпитопы, специфичные для классического и вариантного штаммов ibdv
ES2217967B1 (es) * 2003-03-31 2006-01-01 Consejo Sup. Investig. Cientificas Procedimiento de produccion de particulas virales vacias (vlps) del virus inductor de la bursitis infecciosa (ibdv), composiciones necesarias para su puesta a punto y su uso en la elaboracion de vacunas frente al ibdv.
ES2307346B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias (vlps(-vp4)) del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
ES2307345B1 (es) * 2004-01-21 2009-11-13 Consejo Sup. Investig. Cientificas Capsidas vacias quimericas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), su procedimiento de obtencion y aplicaciones.
NZ549687A (en) * 2004-03-12 2008-08-29 Wyeth Corp Infectious bursal disease virus antigenic isolates and vaccines
US7244432B2 (en) * 2004-12-08 2007-07-17 University Of Maryland Biotechnology Institute Infectious bursal disease virus (IBDV) variant from Georgia
US7491399B2 (en) 2005-06-23 2009-02-17 University Of Maryland Biotechnology Institute In Ovo vaccine against infectious bursal disease
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
WO2007020017A1 (en) * 2005-08-12 2007-02-22 Bionostra, S.L. Composition for bird immunization administered by aerosol
EP2601969B1 (de) 2006-09-29 2016-03-30 Takeda Vaccines, Inc. Norovirus-impfstoff-formulierungen
KR20150129042A (ko) 2007-09-18 2015-11-18 다케다 백신즈 인코포레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
ES2659586T3 (es) * 2008-05-09 2018-03-16 Chimera Pharma S.L.U. Proteínas de fusión quiméricas y partículas similares a virus de VP2 de Birnavirus
PL2324113T3 (pl) * 2008-08-08 2018-08-31 Takeda Vaccines, Inc. Cząstki wirusopodobne zawierające złożone kapsydowe sekwencje aminokwasowe do zwiększonej reaktywności krzyżowej
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
CN108567975A (zh) 2011-07-11 2018-09-25 武田疫苗股份有限公司 胃肠外诺如病毒疫苗配制剂
CN112159480B (zh) * 2020-10-15 2022-03-22 福建农林大学 一种鸡传染性法氏囊病病毒多抗原表位蛋白及其应用
CN112409454B (zh) * 2020-11-04 2022-07-05 青岛农业大学 一种法氏囊七肽及其制备方法和应用
CN112375125B (zh) * 2020-11-23 2021-09-28 东北农业大学 一种多肽及其在预防鸡传染性法氏囊病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908305A (en) * 1987-06-14 1990-03-13 The University Of Maryland Competitive elisa for determination of neutralizing IBDV antibody
EP0474676A4 (en) * 1989-05-30 1993-02-24 The Commonwealth Scientific And Industrial Research Organization Production of ibdv vp2 in highly immunogenic form
JPH05501064A (ja) * 1990-05-04 1993-03-04 ユニバーシティ　オブ　メリーランド　アット　カレッジ　パーク Ｉｂｄｖタンパク質に関連する特異的ｄｎａ配列並びにベクター、宿主およびワクチン
US5595912A (en) * 1990-05-04 1997-01-21 University Of Maryland College Park Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination

Also Published As

Publication number Publication date
US5788970A (en) 1998-08-04
DK0755259T3 (da) 2005-11-28
EP0755259A4 (de) 1999-12-22
DE69534354T2 (de) 2006-03-23
AU2129195A (en) 1995-10-17
CA2186856A1 (en) 1995-10-05
US6017759A (en) 2000-01-25
EP0755259A1 (de) 1997-01-29
JP2005200420A (ja) 2005-07-28
DE69534354D1 (de) 2005-09-08
EP0755259B1 (de) 2005-08-03
AU696656B2 (en) 1998-09-17
ES2249769T3 (es) 2006-04-01
US6156314A (en) 2000-12-05
JPH09510873A (ja) 1997-11-04
WO1995026196A1 (en) 1995-10-05

Similar Documents

Publication Publication Date Title
ATE300950T1 (de) Chimäre cdna-klone des virus der infektiösen bursal-krankheit, expressionsprodukte und darauf basierende impfstoffe
Zanetti et al. The immunology of new generation vaccines
Cox et al. Rabies virus glycoprotein. II. Biological and serological characterization
CN100534529C (zh) 抗原的有序分子呈递，制备及使用的方法
PT91881A (pt) Processo para a preparacao de novas proteinas e peptideos de hiv uteis no diagnostico, profilaxia ou terapia da sida
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
EP2425848A3 (de) Influenza-Immunogen und Impfstoff
NO20002413L (no) Antistoffer mot Moraxella proteiner og anvendelse derav, samt sett for pÕvisning av antigen og farmasøytisk preparat som inneholder antistoffer
NO20050894L (no) Vaksinesammensetninger inneholdende beta-l-6-antigenmatriser
Wang et al. Virus-like particles of hepatitis B virus core protein containing five mimotopes of infectious bursal disease virus (IBDV) protect chickens against IBDV
NZ232505A (en) Conjugate comprising hepatitis b core antigen (hbcag) particles coupled to a polypeptide with an antigenic epitope
Arnon Synthetic peptides as the basis for future vaccines
WO1998046725A3 (en) Attenuated, invasive vaccines against fish pathogens
Francis Peptide vaccines for viral diseases
WO1993020846A1 (en) Recombinant influenza vaccines
Agterberg et al. Protection of guinea-pigs against foot-and-mouth disease virus by immunization with a PhoE-FMDV hybrid protein
WO1991003255A1 (en) Polypeptide vaccines against foot-and-mouth disease virus
US4946676A (en) Vaccine comprising an immunogenic protein and, as an adjuvant, a substantially non-immunogenic, sequentially homologous peptide
Alexandrenne et al. Generating antibodies against the native form of the human prion protein (hPrP) in wild-type animals: a comparison between DNA and protein immunizations
CY1105176T1 (el) Χιμαιρικα νουκλεϊνικα οξεα και πολυπεπτιδια του ιου της λυσσας
Balamurugan et al. Biotechnology in the production of recombinant vaccine or antigen for animal health
MX2022007217A (es) Vacuna epitópica para virus de fiebre porcina africana.
Osterhaus et al. Modulation of the immune system towards antiviral immune response using anti-idiotypic structures
KR930012826A (ko) 변형된 소의 헤르페스바이러스 타입 1에 기초한 백신
Gerin et al. Recombinant DNA and synthetic peptide approaches to HBV vaccine development: Immunogenicity and protective efficacy in chimpanzees.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0755259

Country of ref document: EP

REN Ceased due to non-payment of the annual fee